Blog

Nelson Advisors has been invited to Judge the UCL GBSH Dragons' Den Final 2026 taking place on June 24th 2026.&nbsp;The UCL GBSH Dragons’ Den Final is an annual live pitching competition where UCL Global Business School for Health students pitch healthcare start‑ups to a panel of “Dragons” (investors and entrepreneurs), competing for cash prizes and a year of mentoring.What the event isThe competition is run by UCL’s Global Business School for Health as a flagship entrepreneurship event focused on innovations that improve healthcare delivery and outcomes. It is a live, in‑person evening pitching event, typically held in late June at UCL, with an audience of students, staff, and external guests. Who can enter The most recent editions are open to all GBSH postgraduate and MBA Health students with innovative business ideas in any part of the health ecosystem (digital health, biotech, pharma, health management, public health, etc.). The inaugural 2023 event was broader, allowing any UK postgraduate student with a healthcare business idea to compete, not just those from UCL GBSH. Format and prizes Applicants go through a multi‑round selection process, with several rounds of screening before reaching the final live pitch. At the final, 8–10 shortlisted teams pitch their ideas to a panel of Dragons drawn from healthcare investment, entrepreneurship, and industry leadership. All finalists receive a cash contribution to help start their ventures, and the winning team receives a larger cash prize (recently around £4,000) plus a year of expert mentoring. Recent final and winner In the third annual Dragons’ Den Final (2025), five finalist teams pitched healthcare innovations spanning digital health, public health, and biotech. The winning team, Lumina, presented an AI‑powered perinatal mental health platform, which impressed the judges for its scalability, clinical relevance, and existing pilot activity in the United States. Judges highlighted Lumina’s potential for industry partnerships and policy impact, and the founders described the competition as transformative for turning academic work into a real‑world venture. Why it matters The Final gives health‑focused postgraduates hands‑on experience in venture creation: refining a business model, pitching to investors, and receiving critical feedback. It also acts as a networking hub, connecting student founders with healthcare investors, operators, and mentors who can support commercialisation of their ideas beyond the university setting.

Nelson Advisors invited to Judge the UCL GBSH Dragons' Den Final 2026

The European healthcare technology landscape has reached a definitive inflection point in 2026, transitioning from a period of speculative, venture subsidised fragmentation into a disciplined era defined by industrial maturity and strategic consolidation. At the vanguard of this transformation is Doctolib, a platform that has successfully navigated the post-pandemic recalibration to emerge as the dominant digital health infrastructure provider across France, Germany, and Italy. The acquisition of the London-based startup Medicus Health in May 2026 represents the final, critical piece of the company’s strategic "jigsaw" ahead of its anticipated initial public offering (IPO). This expansion into the United Kingdom is not merely a geographic addition but a sophisticated play to integrate into the National Health Service (NHS) ecosystem, leveraging a rare window of regulatory openness in the British primary care IT market. &nbsp; The strategic move comes at a time of significant regulatory flux in Doctolib’s largest markets. In Germany, the implementation of the Digital-Gesetz (DigiG) and the Health Data Use Act (GDNG) has mandated a shift toward interoperability and performance-based reimbursement, placing intense pressure on legacy business models while creating a "compliance moat" for technologically agile players.&nbsp; &nbsp;&nbsp; Simultaneously, the success of the Dottori.it acquisition in Italy has provided a blueprint for cross-border expansion, proving that the localized "evangelization" of healthcare professionals can overcome fragmented market conditions.&nbsp; &nbsp;&nbsp; By securing a foothold in England’s GP practice network through Medicus Health, Doctolib is positioning its artificial intelligence (AI) and "Operating System" vision at the heart of European clinical workflows, aiming to replace administrative friction with a unified, data-driven environment.Click here to read our full report <a href="https://www.healthcare.digital/single-post/doctolib-s-acquisition-of-medicus-health-to-enter-the-uk-market">https://www.healthcare.digital/single-post/doctolib-s-acquisition-of-medicus-health-to-enter-the-uk-market</a>Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>

Doctolib’s acquisition of Medicus Health to enter the UK market

Milken Institute Global Conference 2026The Milken Institute Global Conference 2026, held May 4-6 th in Beverly Hills, highlighted several breakthrough healthcare technology and AI themes centered on translating innovation into scalable, resilient systems. The conference emphasized precision medicine, artificial intelligence, next-generation therapeutics, and cross-sector collaboration as strategic priorities at the intersection of innovation, investment, and policy.AI-Accelerated Discovery and Development AI-enabled drug discovery emerged as a major theme, with AI positioned to accelerate drug development through deeper collaboration between technology and pharmaceutical companies. The conference featured discussions on how AI is transforming the global healthcare ecosystem, from turbo-charging drug development to benefiting healthcare delivery and access, with stakeholders intensifying AI adoption to improve efficiency, accuracy, affordability, and trust. Sessions examined separating fact from fiction regarding AI benefits while minimizing risks in defining a new age of healthcare.Multimodal Data Platforms Multimodal data platforms represented a significant innovation theme, with technologies integrating imaging, EHR data, lab values, clinical notes, and genomics to enable more accurate, context-aware clinical decisions. The conference highlighted how multimodal AI systems combine pathology, radiology, omics, and clinical notes to improve predictive performance and identify biomarkers invisible to single-modality approaches. These platforms are creating opportunities to build entirely new categories of healthcare solutions.Next-Generation Diagnostics The conference spotlighted next-generation diagnostics as opening new territory for health investing, with emphasis on AI-enabled diagnostic capabilities and early detection tools. Discussions covered how diagnostic performance increasingly depends on AI rather than just hardware or assays, with differentiation shifting toward multimodal intelligence solutions that combine imaging, EHR, lab, and genomic data into integrated views. Point-of-care diagnostics were discussed as critical for improving healthcare delivery and facilitating antimicrobial stewardship.Innovative Care Models and Regulatory Challenges The conference addressed innovative care models alongside significant headwinds facing the industry, including FDA uncertainty, pricing policies, and tariffs impacting the translation of advances into practical impact. Sessions examined what will be needed to foster innovations poised to define the next decade of opportunity across the health ecosystem. The regulatory environment featured prominently, with discussions on FDA staffing concerns balanced against support for accelerated approval pathways for rare disease treatments.Healthcare Investment and Cross-Sector Collaboration Investment themes centered on how private capital is emerging as a critical lever for transforming health systems globally, with panels examining where compelling opportunities lie, how risk is being priced and structured, and requirements to move capital from commitment to impact. The conference reinforced the role of cross-sector collaboration in shaping the future of care delivery worldwide, with healthcare positioned as a strategic focus at the crossroads of innovation, investment, and policy.Source: <a href="https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research" data-mce-href="https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research">https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research</a>Milken Institute Global Conference 2026The Milken Institute Global Conference is the Institute’s flagship annual convening, bringing together leaders across health, finance, business, technology, philanthropy, and public policy. The 2026 conference focuses on translating recent disruption and innovation into practical solutions for a more sustainable, equitable, and resilient future.It is a unique experience in which individuals with the capital and influence to change the world connect with those whose expertise and creativity are reinventing health, finance, business, technology, philanthropy, industry, and society.The 29th annual Global Conference will convene our diverse and forward-thinking community to tackle these urgent issues and seize opportunities to collectively shape a more sustainable, equitable, and resilient future.&nbsp;Join us as we reflect on the disruptions and innovations of the recent past and translate lessons learned into building meaningful, healthy, and prosperous lives for all.Follow the conversation with #MIGlobal

Key Healthcare Technology and Healthcare AI themes from Milken Conference 2026

The global healthcare technology and medical technology sectors have transitioned into a definitive era of disciplined industrial maturity as of the first half of 2026. This period, characterised as the emergence of HealthTech 2.0, represents a structural shift from the speculative, volume-driven dealmaking of the pandemic era toward high-value, transformative transactions grounded in fundamental business metrics.&nbsp; &nbsp;&nbsp; In this new phase, valuation is no longer merely a reflection of prospective market capture; instead, it is predicated on a company’s deep integration into clinical pathways, its regulatory fortitude under a maturing global framework and its capacity to deliver a sustainable, measurable return on investment to health systems facing unprecedented fiscal constraints.&nbsp; &nbsp;&nbsp; As 2026 unfolds, the market is witnessing a selective recovery where high-quality assets with defensible moats command premium multiples, while those lacking operational leverage or regulatory readiness face significant compression.To read our full report please click here <a href="https://www.healthcare.digital/single-post/healthtech-and-medtech-m-a-2026-valuation-multipliers">https://www.healthcare.digital/single-post/healthtech-and-medtech-m-a-2026-valuation-multipliers</a> &nbsp;

HealthTech and MedTech M&A 2026 Valuation Multipliers

The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a decade of speculative, venture-subsidised experimentation to an era of disciplined industrial maturity.This transformation is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility.&nbsp;Central to this transition is the emergence of the "Founder Banker," a new class of corporate financial advisor and entrepreneur who combines deep operational pedigree, having built, scaled and exited their own ventures, with sophisticated investment banking and private equity expertise. These individuals occupy a critical niche in the contemporary M&amp;A landscape, bridging the widening gap between digital economy metrics and the complex, often opaque, regulatory realities of modern healthcare systems.Banker-Founders: The Professionalisation of Healthtech LeadershipThe new wave of competitive advantage is increasingly driven by founders who moved from the upper echelons of corporate finance into Healthtech leadership. These individuals bring a level of "financial engineering" and strategic long-termism that traditional clinician-founders often struggle to replicate.Ali Parsa: From Goldman Sachs to Babylon HealthParsa's financial background was instrumental in Babylon’s ability to attract unprecedented levels of capital, including a $550 million funding round in 2019 backed by Saudi Arabia's Public Investment Fund.Stanislas Niox-Chateau: The Strategist Behind DoctolibIn France, Stanislas Niox-Chateau has demonstrated a more industrially disciplined approach to the banker-founder model.Johannes Schildt: Finance and the Scaling of Kry/LiviCo-founder and CEO of the Swedish digital health giant Kry (known as Livi in France and the UK), similarly leverages a background at Stifel Financial Corp to navigate the capital-intensive digital health landscape.Jean-Charles Samuelian-Werve: The Systems Thinker at AlanAt Alan, he has rebuilt health insurance from the ground up, scaling to over 500,000 members and a $4 Billion valuation.For founders, the emergence of the "Founder Banker" provides a vital roadmap to liquidity, offering the "operational empathy" required to navigate the Series A and B Crunches and achieve high-value exits.To read the full report, click here <a href="https://www.healthcare.digital/single-post/founder-bankers-and-banker-founders-new-competitive-advantages-in-european-healthtech-and-medtech">https://www.healthcare.digital/single-post/founder-bankers-and-banker-founders-new-competitive-advantages-in-european-healthtech-and-medtech</a>

Founder Bankers and Banker Founders: New Competitive Advantages in European HealthTech and MedTech

Nelson Advisors has been referenced in the Expert Opinions on Digital Health Innovations series - 'Exploration of Digital Health Technologies' within the &nbsp;'A call for responsible innovation in pediatric health care' publication.Source: <a href="https://www.explorationpub.com/Journals/edht/Special_Issues/365" data-mce-href="https://www.explorationpub.com/Journals/edht/Special_Issues/365">https://www.explorationpub.com/Journals/edht/Special_Issues/365</a>About the Special lssue This special issue seeks to gather expert opinions from a multidisciplinary group, including scientists, scholars, clinicians, bioengineers, and industry leaders, on the transformative potential of digital health innovations. We aim to explore how these technologies are reshaping healthcare delivery, patient outcomes, and clinical practices across diverse specialties, including geriatrics, orthopedics, general surgery, dentistry, genetics, and other fields.Submissions are encouraged to address the following themes:Impact of digital health innovations on clinical practice: How are emerging technologies, such as artificial intelligence, telemedicine, wearables, and mobile health applications, influencing diagnosis, treatment, and patient management in specific specialties? Patient perspectives: How are patients experiencing and engaging with digital health tools? What are the benefits and challenges of these technologies from patients’ point of view? Ethical, legal, and social implications (ELSI): What are the ethical considerations surrounding data privacy, security, and algorithmic bias in the context of digital health? How can we ensure equitable access to these innovations? Future directions and challenges: What are the most promising avenues for future research and development in digital health? What barriers and challenges need to be overcome to realize the full potential of these technologies? We invite original research articles, reviews, case studies, and perspectives that shed light on the current state and future trajectory of digital health innovations, providing valuable insights for clinicians, researchers, policymakers, and industry stakeholders.A call for responsible innovation in pediatric health careExplor Digit Health Technol. 2026;4:101178 DOI: https://doi.org/10.37349/edht.2026.101178Received: September 01, 2025 Accepted: November 17, 2025 Published: January 06, 2026Academic Editor: Marco Tatullo, University of Bari, ItalyThe article belongs to the special issue Expert Opinions on Digital Health InnovationsSource: <a href="https://www.explorationpub.com/Journals/edht/Article/101178">https://www.explorationpub.com/Journals/edht/Article/101178</a>

Nelson Advisors

Blog

Nelson Advisors invited to Judge the UCL GBSH Dragons' De...

Doctolib’s acquisition of Medicus Health to enter the UK ...

Key Healthcare Technology and Healthcare AI themes from M...

HealthTech and MedTech M&A 2026 Valuation Multipliers

Founder Bankers and Banker Founders: New Competitive Adva...

Nelson Advisors referenced in the Expert Opinions on Digi...